Inhibrx Biosciences, Inc.

Historical 13F Holders

Symbol
INBX
CUSIP
45720N103
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 45720N103 since 12/18/2024, newest first.

Filer % of Class Filed
Schonfeld Strategic Advisors LLC 13G 5.3% 8/14/2026
Event 6/30/2026
Perceptive Advisors LLC 13G/A Amendment 2
10.0% 8/14/2026
Event 6/30/2026
Viking Global Investors LP 13G/A Amendment 3
9.3% 8/14/2026
Event 6/30/2026
Bank of America Corp /DE/ 13G 5.9% 8/3/2026
Event 6/30/2026
Perceptive Advisors LLC 13G/A Amendment 1
10.0% 5/15/2026
Event 3/31/2026
Viking Global Investors LP 13G/A Amendment 2
10.0% 5/15/2026
Event 3/31/2026
Viking Global Investors LP 13G/A Amendment 1
10.0% 2/17/2026
Event 12/31/2025
Morgan Stanley 13G
7.9% 2/11/2026
Event 12/31/2025
BlackRock, Inc. 13G 5.3% 1/21/2026
Event 12/31/2025
BlackRock, Inc. 13G/A Amendment 1 4.7% 10/17/2025
Event 9/30/2025
Jon Faiz Kayyem 13D/A Amendment 1
7.9% 2/26/2025
Event 6/3/2024
Mark Lappe 13D/A Amendment 1 6.4% 2/26/2025
Event 9/12/2024
BlackRock, Inc. 13G 5.7% 2/4/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 5 7.19 k $720 k
2026 Q2 178 15.1 M $1.37 B
2026 Q1 149 12.7 M $855 M
2025 Q4 159 12.8 M $1.01 B
2025 Q3 108 10.5 M $354 M
2025 Q2 92 10.4 M $149 M
2025 Q1 97 10.8 M $151 M
2024 Q4 111 11.2 M $172 M
2024 Q3 111 8.93 M $140 M
2024 Q2 99 9.94 M $141 M